Immuron CEO, Steven Lydeamore, to host an investor webinar
August 29 2022 - 7:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and
clinical-stage biopharmaceutical company with a proprietary
technology platform for prevention and treatment of gut-mediated
diseases; invites investors to join a live webcast hosted by Steven
Lydeamore, CEO of Immuron Limited.
Wednesday, 7 September 2022 at 9.00am Australian Eastern Standard
Time (AEST).Register in advance for this
webinar:https://us02web.zoom.us/webinar/register/WN_sCS7O27uRxWQPC3Z6ILa8gAfter
registering, you will receive a confirmation email containing
information about joining the webinar. |
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN) is a commercial and clinical-stage
Australian biopharmaceutical company with a proprietary technology
platform focused on a novel class of orally delivered polyclonal
antibodies produced from hyperimmune antibody-rich bovine
colostrum, for prevention and treatment of gut-mediated
diseases.For more information visit: http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024